QualityStocksNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Collects 2b Disease Trial Data; Receives NASDAQ Notice Regarding Annual Report
180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, has announced collection of all patient data for its phase 2b Dupuytren’s disease trial, which was sponsored by the University of Oxford. The double-blind placebo-controlled trial involved 181 patients … Continue reading “QualityStocksNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Collects 2b Disease Trial Data; Receives NASDAQ Notice Regarding Annual Report”